Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 78

1.

A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings.

Chiu PK, Ng CF, Semjonow A, Zhu Y, Vincendeau S, Houlgatte A, Lazzeri M, Guazzoni G, Stephan C, Haese A, Bruijne I, Teoh JY, Leung CH, Casale P, Chiang CH, Tan LG, Chiong E, Huang CY, Wu HC, Nieboer D, Ye DW, Bangma CH, Roobol MJ.

Eur Urol. 2018 Nov 2. pii: S0302-2838(18)30842-X. doi: 10.1016/j.eururo.2018.10.047. [Epub ahead of print]

PMID:
30396635
2.

ALDH1-positive intratumoral stromal cells indicate differentiated epithelial-like phenotype and good prognosis in prostate cancer.

Nastały P, Filipska M, Morrissey C, Eltze E, Semjonow A, Brandt B, Pantel K, Bednarz-Knoll N.

Transl Res. 2019 Jan;203:49-56. doi: 10.1016/j.trsl.2018.08.007. Epub 2018 Sep 12.

PMID:
30287243
3.

Somatic aberrations of BRCA1 gene are associated with ALDH1, EGFR, and tumor progression in prostate cancer.

Omari A, Nastały P, Stoupiec S, Bałabas A, Dąbrowska M, Bielińska B, Huss S, Pantel K, Semjonow A, Eltze E, Brandt B, Bednarz-Knoll N.

Int J Cancer. 2018 Sep 28. doi: 10.1002/ijc.31905. [Epub ahead of print]

PMID:
30265376
4.

The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes.

van Strijp D, de Witz C, Vos PC, den Biezen-Timmermans E, van Brussel A, Wrobel J, Baillie GS, Tennstedt P, Schlomm T, Heitkötter B, Huss S, Bögemann M, Houslay MD, Bangma C, Semjonow A, Hoffmann R.

Prostate Cancer. 2018 Jul 26;2018:5821616. doi: 10.1155/2018/5821616. eCollection 2018.

5.

Discordant prostate specific antigen test results despite WHO assay standardization.

Boegemann M, Arsov C, Hadaschik B, Herkommer K, Imkamp F, Nofer JR, Gerß J, Albers P, Semjonow A.

Int J Biol Markers. 2018 Aug;33(3):275-282. doi: 10.1177/1724600818754750. Epub 2018 May 8.

PMID:
29734838
6.

The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone.

Boegemann M, Schlack K, Thomes S, Steinestel J, Rahbar K, Semjonow A, Schrader AJ, Aringer M, Krabbe LM.

Int J Mol Sci. 2017 Feb 11;18(2). pii: E380. doi: 10.3390/ijms18020380.

7.

[Results of a psychooncological group intervention in male cancer patients aged 60 years or older].

Schneider G, Kropff B, Unrath M, Floeth S, Semjonow A, Doering S.

Z Psychosom Med Psychother. 2016 Dec;62(4):336-352. German. No abstract available.

PMID:
27924697
8.

Blind Biobanking of the Prostatectomy Specimen: Critical Evaluation of the Existing Techniques and Development of the New 4-Level Tissue Extraction Model With High Sampling Efficacy.

Tolkach Y, Eminaga O, Wötzel F, Huss S, Bettendorf O, Eltze E, Abbas M, Imkamp F, Semjonow A.

Prostate. 2017 Mar;77(4):396-405. doi: 10.1002/pros.23278. Epub 2016 Nov 16.

PMID:
27862105
9.

Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer.

Schlack K, Krabbe LM, Fobker M, Schrader AJ, Semjonow A, Boegemann M.

Int J Mol Sci. 2016 Sep 9;17(9). pii: E1520. doi: 10.3390/ijms17091520.

10.

Influence of Statins on Survival Outcome in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone Acetate.

Boegemann M, Schlack K, Fischer AK, Gerß J, Steinestel J, Semjonow A, Schrader AJ, Krabbe LM.

PLoS One. 2016 Sep 1;11(9):e0161959. doi: 10.1371/journal.pone.0161959. eCollection 2016.

11.

Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer.

Mikah P, Krabbe LM, Eminaga O, Herrmann E, Papavassilis P, Hinkelammert R, Semjonow A, Schrader AJ, Boegemann M.

BMC Cancer. 2016 Mar 14;16:214. doi: 10.1186/s12885-016-2260-y.

12.

Correlation of Intraprostatic Tumor Extent with ⁶⁸Ga-PSMA Distribution in Patients with Prostate Cancer.

Rahbar K, Weckesser M, Huss S, Semjonow A, Breyholz HJ, Schrader AJ, Schäfers M, Bögemann M.

J Nucl Med. 2016 Apr;57(4):563-7. doi: 10.2967/jnumed.115.169243. Epub 2016 Jan 14.

13.

Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate cancer Research International: Active Surveillance (PRIAS) study.

Bokhorst LP, Lepistö I, Kakehi Y, Bangma CH, Pickles T, Valdagni R, Alberts AR, Semjonow A, Strölin P, Montesino MF, Berge V, Roobol MJ, Rannikko A.

BJU Int. 2016 Sep;118(3):366-71. doi: 10.1111/bju.13410. Epub 2016 Feb 12.

14.

Analysis of topographical distribution of prostate cancer and related pathological findings in prostatectomy specimens using cMDX document architecture.

Eminaga O, Semjonow A, Eltze E, Bettendorf O, Schultheis A, Warnecke-Eberz U, Akbarov I, Wille S, Engelmann U.

J Biomed Inform. 2016 Feb;59:240-7. doi: 10.1016/j.jbi.2015.12.009. Epub 2015 Dec 17.

15.

Comparison of Two Prostate Cancer Risk Calculators that Include the Prostate Health Index.

Roobol MJ, Vedder MM, Nieboer D, Houlgatte A, Vincendeau S, Lazzeri M, Guazzoni G, Stephan C, Semjonow A, Haese A, Graefen M, Steyerberg EW.

Eur Urol Focus. 2015 Sep;1(2):185-190. doi: 10.1016/j.euf.2015.06.004. Epub 2015 Jun 23.

PMID:
28723432
16.

Preoperative Serum Prostate-Specific Antigen Levels Vary According to the Topographical Distribution of Prostate Cancer in Prostatectomy Specimens.

Eminaga O, Hinkelammert R, Abbas M, Wötzel F, Eltze E, Bettendorf O, Boegemann M, Semjonow A.

Urology. 2015 Oct;86(4):798-804. doi: 10.1016/j.urology.2015.07.029. Epub 2015 Aug 6.

PMID:
26255036
17.
18.

Exploring prostate cancer genome reveals simultaneous losses of PTEN, FAS and PAPSS2 in patients with PSA recurrence after radical prostatectomy.

Ibeawuchi C, Schmidt H, Voss R, Titze U, Abbas M, Neumann J, Eltze E, Hoogland AM, Jenster G, Brandt B, Semjonow A.

Int J Mol Sci. 2015 Feb 11;16(2):3856-69. doi: 10.3390/ijms16023856.

19.

Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial.

Wiegel T, Bartkowiak D, Bottke D, Thamm R, Hinke A, Stöckle M, Rübe C, Semjonow A, Wirth M, Störkel S, Golz R, Engenhart-Cabillic R, Hofmann R, Feldmann HJ, Kälble T, Siegmann A, Hinkelbein W, Steiner U, Miller K.

Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):288-94. doi: 10.1016/j.ijrobp.2014.09.039. Epub 2014 Nov 20.

PMID:
25445556
20.

Preoperative prostate-specific antigen isoform p2PSA ≤ 22.5 pg/ml predicts advanced prostate cancer in patients undergoing radical prostatectomy.

Eminaga O, Bögemann M, Breil B, Titze U, Wötzel F, Eltze E, Bettendorf O, Semjonow A.

Urol Oncol. 2014 Nov;32(8):1317-26. doi: 10.1016/j.urolonc.2014.04.018. Epub 2014 Jun 2.

PMID:
24893699

Supplemental Content

Loading ...
Support Center